Rare
lephants
Screener
Toggle theme
Novartis AG
NVSEF
·
Healthcare, Drug Manufacturers - General, Switzerland
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
Total Cash from Operations:
$15.70B
Line Item
Value
% of Total
Stock Repurchases
$10.91B
69.5%
Other Financing
$4.79B
30.5%
Net Cash Flow
$0
0.0%
Download CSV
